Latest Conference Articles

Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.

Explore the vital role of antibody-drug conjugates in precision oncology for GI malignancies, focusing on managing payload-dependent toxicities effectively.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival (PFS) in patients with metastatic colorectal cancer.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

Giredestrant shows lower treatment discontinuation rates compared to standard therapy and is being explored in combination with other drugs.

Explore how thalidomide derivatives enhance T-cell responses and combat exhaustion in multiple myeloma therapies for improved patient outcomes.

New research highlights nivolumab AVD as a promising new standard of care for advanced Hodgkin lymphoma, showing improved survival rates and tolerability.

Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.

The HER2CLIMB-05 trial reveals tucatinib enhances progression-free survival in HER2-positive metastatic breast cancer, offering new hope for patients.

A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for advanced cancer treatments.

Pumitamig shows promise as a bispecific antibody, enhancing immunotherapy effectiveness in treating triple-negative breast cancer patients.

Dr. Michael Wang discusses ECHO long-term data, revealing that concurrent therapy for mantle cell lymphoma significantly outperforms sequential treatment.

UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, targeting unmet clinical needs.

Discover groundbreaking results from the lidERA study, showcasing giredestrant's potential to redefine treatment for early breast cancer patients.

Sacituzumab govitecan shows improved survival and quality of life in advanced triple-negative breast cancer, outperforming standard chemotherapy in recent trials.

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.

A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria as key indicators of patient survival.

Erdafitinib shows promising efficacy and manageable safety in treating recurrent gliomas with F3T3 gene fusions, according to recent trial findings.

A new trial shows promising results for combining niraparib and dostarlimab in treating triple-negative breast cancer with BRCA mutations.

Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results.

Premenopausal women with early breast cancer favor GnRHa therapy for fertility preservation during chemotherapy, with varying acceptance based on age and hormone receptor status.

A RAD51-based assessment identifies HER2-negative breast cancer patients likely to benefit from olaparib, enhancing treatment selection and outcomes.

Real acupuncture significantly enhances cognitive health in breast cancer survivors, outperforming usual care and showing promise over sham treatments.